TrialBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Robert Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.